Peptides for fertility and hormones research is unusual among the categories in this catalogue in that its underlying biology is genuinely well understood. The hypothalamic-pituitary-gonadal axis is one of the best-mapped control systems in endocrinology: kisspeptin neurons drive the GnRH pulse generator, GnRH pulses drive pituitary LH and FSH release, and the gonadotropins drive gonadal steroid and gamete production, with steroid feedback closing the loop. Every compound in this category acts at a defined point on that pathway. The complication is that several act in the suppressive direction, which is not what the category name implies. This overview maps the axis, compares the reference standards, and sets out selection logic. All material is supplied for laboratory research use only.
The axis, and where each compound acts
The pulse generator sits in the arcuate nucleus, in neurons co-expressing kisspeptin, neurokinin B and dynorphin — the KNDy population, whose synchronised activity produces the GnRH pulses that everything downstream depends on. Kisspeptin acts on KISS1R to drive GnRH release. GnRH reaches the anterior pituitary through the portal circulation and, in pulses, stimulates gonadotroph secretion of LH and FSH. LH acts on Leydig and theca cells for steroidogenesis; FSH acts on Sertoli and granulosa cells for gametogenesis. Sex steroids feed back negatively at both hypothalamus and pituitary.
Compounds map cleanly onto that diagram. Kisspeptin analogs act at the top. GnRH and its agonists act one level down, with the direction depending entirely on administration pattern. Gonadotropins and their analogs act at the gonad. Selective estrogen receptor modulators act by removing the feedback brake rather than by stimulating anything directly.
What this research measures
Frequent sampling is the defining methodological requirement. LH is secreted in discrete pulses with an interpulse interval measured in tens of minutes, so a single blood sample captures an arbitrary point on that oscillation and can register a peak or trough regardless of treatment. Standard protocols sample every ten to fifteen minutes over four to eight hours and analyse with a pulse detection algorithm. Other endpoints include FSH, testosterone, estradiol and progesterone; anti-Müllerian hormone as an ovarian reserve marker; sperm concentration, motility and morphology; ovarian follicle counts on histology; and in rodents, vaginal cytology staging to track reproductive stage. Electrophysiological recording of multi-unit activity in the arcuate nucleus is the direct readout of pulse generator function and is the gold standard in mechanistic work.
The classes studied
Kisspeptin analogs
Kisspeptin-10 is the C-terminal decapeptide of kisspeptin-54, at 1302.47 Da, acting at KISS1R — formerly GPR54. Its discovery is one of the cleanest stories in reproductive endocrinology: loss-of-function mutations in KISS1R were found to cause hypogonadotropic hypogonadism in humans, establishing the receptor as the essential gate on GnRH release. Human physiology studies from academic groups, notably at Imperial College London, have examined LH response to administration in health and in reproductive disorders. Its short measured half-life is the practical constraint, and longer-acting analogs exist precisely to address it.
GnRH and its agonists
Gonadorelin is GnRH itself, the decapeptide, at 1182.29 Da. It is used diagnostically to test pituitary gonadotroph responsiveness, and in pulsatile administration it stimulates the axis. Triptorelin is a superagonist carrying a D-tryptophan substitution at position 6 that resists degradation and binds with higher affinity, at 1311.45 Da. Its behaviour is the counterintuitive fact of this whole category: continuous exposure to a GnRH agonist causes receptor downregulation and gonadotroph desensitisation, suppressing LH and FSH output after an initial flare. That is the basis of its clinical use in hormone-sensitive conditions, and it means the same molecular class produces opposite endocrine outcomes depending on how it is presented.
Gonadotropins
HCG is a glycoprotein hormone that shares its alpha subunit with LH, FSH and TSH and acts at the LH/CG receptor. Its longer half-life relative to LH comes from the extended C-terminal peptide on its beta subunit. HMG, menotropins, is a urinary-derived preparation with both FSH and LH activity. Both are prescription medicines, listed in this catalogue for reference only. They are also glycoproteins rather than synthetic peptides, which means their potency is expressed in international units by bioassay rather than in milligrams by mass — a distinction that matters when designing any protocol involving them.
Feedback modulators
Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator at 405.96 Da as the citrate. It works by blocking estrogen negative feedback at the hypothalamus and pituitary, which raises endogenous LH and FSH — an indirect mechanism that depends on an intact axis to work at all. Its development programme for a specific male indication did not result in approval, and it is an unapproved investigational compound.
Comparison table: reproductive axis reference standards
| Compound | Level of action | MW | Target | Direction | Research sizes |
|---|---|---|---|---|---|
| Kisspeptin-10 | Hypothalamic, upstream of GnRH | 1302.47 Da | KISS1R (GPR54) | Stimulatory | 5 mg, 10 mg |
| Gonadorelin | Pituitary gonadotroph | 1182.29 Da | GnRH receptor | Stimulatory when pulsatile | 2-10 mg |
| Triptorelin | Pituitary gonadotroph | 1311.45 Da | GnRH receptor superagonist | Suppressive when continuous | 2 mg |
| HCG | Gonad | Glycoprotein | LH / CG receptor | Stimulatory (steroidogenesis) | 5,000-10,000 IU |
| HMG (menotropins) | Gonad | Glycoprotein mixture | FSH and LH activity | Stimulatory (gametogenesis) | 75 IU |
| Enclomiphene | Feedback loop | 405.96 Da | Estrogen receptor modulation | Indirectly stimulatory | 30 mL research liquid |
| Oxytocin | Peripheral reproductive tissue | 1007.19 Da | Oxytocin receptor | Uterine and behavioural | 2-10 mg |
| Kisspeptin troches | Format variant | Sublingual | As kisspeptin-10 | Route comparison work | 500 mcg × 30 |
The direction column is the one that catches people out. Two GnRH-receptor compounds appear in this table with opposite entries, and the difference is not the molecule but the administration pattern.
What the published record shows, by study type
Mechanistic animal work
The KNDy pulse generator model is supported by electrophysiological recording, optogenetic activation and receptor knockout work across several independent laboratories, and it is one of the more solid mechanistic stories in neuroendocrinology. Kisspeptin's necessity for pubertal onset is established genetically in mice and humans alike. GnRH receptor desensitisation under continuous exposure is a classic, thoroughly replicated pharmacological result.
Human physiology
Kisspeptin administration studies in humans have measured LH response in health, in hypothalamic amenorrhoea and in other reproductive conditions, from academic groups working under research protocols. Gonadorelin has long-standing diagnostic use. Triptorelin, HCG and HMG are approved medicines with substantial clinical trial records behind their licensed indications.
Where evidence is thinner
Enclomiphene's development programme did not lead to approval, and it should be described as investigational rather than as an established agent. Research-grade preparations of any compound here have no clinical evidence attached to them — the trial data belongs to pharmaceutical products characterised and manufactured to different standards.
How researchers choose peptides for fertility and hormones
- Which level of the axis? A pulse generator question calls for kisspeptin; a pituitary responsiveness question calls for gonadorelin; a gonadal question calls for a gonadotropin. Testing at the wrong level produces a result about a different part of the system.
- Pulsatile or continuous? Decisive for the GnRH compounds, and the single most common source of confusion in this area. Pulsatile stimulates; continuous suppresses.
- Is the axis intact? Enclomiphene works by removing feedback and requires functioning hypothalamic and pituitary components. In a hypophysectomised or knockout model it has nothing to act through.
- Is sampling adequate? Pulsatile hormones need frequent sampling with pulse detection analysis. Single-time-point LH is not a measurement of axis function.
The catalogue for this research goal is at peptides for fertility and hormones, with the mechanistic grouping under hormonal and fertility peptides. Two comparisons cover the questions asked most often: kisspeptin-10 versus gonadorelin on level of action, and HCG versus HMG on gonadotropin composition.
Formats and handling
Lyophilised vials are standard for the synthetic peptides and allow molar concentration to be set. The glycoprotein hormones are supplied and specified in international units by bioassay rather than by mass, because glycosylation heterogeneity means that equal masses of different preparations do not carry equal biological activity — this is a genuine difference in kind from the synthetic peptides and must be reflected in how a protocol is written. Sublingual troches and nasal formats exist for kisspeptin and are pre-diluted at fixed concentration, useful for route-comparison work and unsuitable where concentration is a variable.
Handling notes: kisspeptin-10 and GnRH are small, stable peptides in lyophilised form but have short measured half-lives in circulation, which is why infusion rather than bolus protocols are common in physiology work. Oxytocin is among the least stable common research peptides in solution and contains a disulfide bridge whose closure should be confirmed on the certificate. Glycoprotein preparations are more temperature-sensitive than synthetic peptides and lose potency with repeated freezing and thawing. All lyophilised material is stored sealed at -20 °C, protected from light, and aliquoted at reconstitution.
Common design errors
The first is single-time-point gonadotropin sampling, for the reason set out above. It is the most common error in this literature and it invalidates the primary endpoint rather than merely weakening it.
The second is ignoring reproductive stage in female animals. Hormone levels and hypothalamic sensitivity vary substantially across the estrous sequence, so unstaged animals introduce a variance term larger than most treatment effects. Vaginal cytology staging is cheap and routine.
The third is confusing units. Synthetic peptides are specified by mass, glycoprotein hormones by bioassay units, and the two cannot be converted into one another. A protocol mixing the conventions without stating which applies where is not reproducible.
The fourth is reading an isolated hormone measurement as a fertility outcome. Serum testosterone or LH is an intermediate; gamete parameters, follicle counts or pregnancy outcomes in an appropriate model are the endpoints that correspond to the claim.
A fifth error is assuming that a hormonal change observed in one sex transfers to the other. The axis is architecturally the same but its regulation is not: negative feedback in males is comparatively steady, while in females it alternates with a positive feedback mode that produces the preovulatory LH surge, mediated through a distinct kisspeptin population in the anteroventral periventricular nucleus. A compound tested only in males has not been characterised in females, and vice versa, and the surge mechanism in particular has no male equivalent.
A sixth is neglecting the time course of gonadal responses. Steroidogenesis responds to gonadotropin stimulation within hours, but gametogenesis operates on a completely different scale — spermatogenesis in humans takes approximately seventy-four days from spermatogonial division to mature sperm, and folliculogenesis from primordial recruitment to ovulation spans several months. A study measuring sperm parameters four weeks after starting an intervention has not allowed a full wave of spermatogenesis to complete, and whatever it measures reflects gametes that were already well advanced when the study began.
Purity, identity and regulatory status
The synthetic peptides are short and should show 98% or better by HPLC with mass-spectrometric identity confirmation. Gonadorelin is C-terminally amidated and N-terminally pyroglutamated, both of which should be confirmed by mass rather than assumed. Triptorelin's defining feature is the D-tryptophan substitution at position 6, which does not change the nominal mass relative to the L-isomer — chirality is confirmed chromatographically, not by mass spectrometry, and this is one of the few places in the catalogue where that distinction has practical consequences. Glycoprotein preparations are characterised by bioassay potency and glycoform profile rather than by HPLC purity.
Triptorelin, HCG and HMG are prescription medicines listed for reference only; the research-grade material is not those products. Enclomiphene is an unapproved investigational compound whose development programme did not result in approval. Kisspeptin-10 and gonadorelin hold no approval as therapeutic agents in the United States, although gonadorelin has diagnostic history. Everything referenced on this page is research-grade material supplied for in-vitro and laboratory research use only, and is not for human or veterinary administration.